1. Cardiovascular risk in patients with alpha-1-antitrypsin deficiency
- Author
-
Sebastian Fähndrich, Frank Biertz, Annika Karch, Björn Kleibrink, Armin Koch, Helmut Teschler, Tobias Welte, Hans-Ulrich Kauczor, Sabina Janciauskiene, Rudolf A. Jörres, Timm Greulich, Claus F. Vogelmeier, Robert Bals, and on behalf of the COSYCONET investigators
- Subjects
Alpha-1-antitrypsin deficiency ,Phenotype ,Cardiovascular disease ,Emphysema ,Personalized medicine ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Alpha-1-antitrypsin deficiency (AATD) is a rare inherited condition caused by mutations of the SERPINA1 gene that is associated with the development of a COPD like lung disease. The comorbidities in patients with AATD-related lung diseases are not well defined. The aim of this study was to analyze the clinical phenotype of AATD patients within the German COPD cohort study COSYCONET (“COPD and SYstemic consequences-COmorbidities NETwork”) cohort focusing on the distribution of comorbidities. Method and results The data from 2645 COSYCONET patients, including 139 AATD patients (110 with and 29 without augmentation therapy), were analyzed by descriptive statistics and regression analyses. We found significantly lower prevalence of cardiovascular comorbidities in AATD patients as compared to non-AATD COPD patients. After correction for age, pack years, body mass index, and sex, the differences were still significant for coronary artery disease (p = 0.002) and the prevalence of peripheral artery disease as determined by an ankle-brachial-index
- Published
- 2017
- Full Text
- View/download PDF